943results about "Genital tract cells" patented technology

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

The invention discloses a site for stably expressing protein in a CHO cell gene NW023276806.1 and application of the site, and belongs to the technical field of biological genes. The site belongs to a fixed position in a CHO cell genome, different protein genes are introduced based on a micro-homologous end connection mechanism through a CRISPR / Cas9 tool, and stable expression is carried out. By adopting a site-specific integration method, a target gene is integrated to a stable expression area in a site-specific manner, repeated high-expression monoclonal screening is effectively avoided, and an MMEJ mechanism is introduced to integrate a donor fragment, so that the research and development time for constructing a stable expression cell strain in biological pharmacy can be effectively shortened, and the cost is reduced.

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

Methods, compositions and devices characterized by in vitro maturation of oocytes. In particular, the present disclosure features methods of inducing oocyte maturation in vitro by co-culturing oocytes of a female subject with an ex vivo composition comprising a plurality of ovarian supporting cells (e.g., granular cells). Additional methods of administering a follicle triggering agent and extracting oocytes from a female subject are also provided. Such methods, compositions, and devices are particularly useful for assisted reproductive technology (ART) procedures.

The invention belongs to the technical field of immunodetection, and discloses a rabbit monoclonal antibody mAb6 of an anti-mouse immune globulin G2a subtype (IgG2a) and application thereof. The rabbit monoclonal antibody mAb6 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence KSVYKNNY, the LCDR2 comprises an amino acid sequence GTN, and the LCDR3 comprises an amino acid sequence AGGYID; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence RFSLSNYR, the HCDR2 comprises an amino acid sequence IFTRGST, and the HCDR3 comprises an amino acid sequence ARGWNS. The rabbit monoclonal antibody disclosed by the invention can be combined with a mouse immune globulin G2a subtype (IgG2a) in a high-specificity manner, can be applied to immunodetection, and provides a basis for further preparation of engineering antibodies.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively cleaved additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which one or more amino acids located at the N-terminal and C-terminal regions are deleted.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb32 or an antigen binding fragment, the anti-T3 antibody mAb32 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is IAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb32 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, and when a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

Provided are a fusion protein (for example, in the form of a bispecific antibody) binding to CD235a and CD3, a preparation method therefor, and a related use thereof.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb68 or an antigen binding fragment, the anti-T3 antibody mAb68 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is TAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb68 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, a clinical sample is detected through a magnetochemiluminescence method, and the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The invention discloses a CD40L-IL-2 fusion protein, preparation thereof and application of the CD40L-IL-2 fusion protein in preparation of drugs for treating tumors. The fusion protein comprises a CD40L trimer or a variant thereof, and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.

The invention relates to a targeted CLDN18.2 antigen binding protein and application thereof, the antigen binding protein comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises an amino acid sequence as shown in SEQ ID NO: 10, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 3.

The present invention relates to a nanobody or antigen-binding fragment thereof that specifically binds to serum albumin, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a host cell comprising same, and related uses. Further, the present invention relates to therapeutic use of the antibody or the antigen-binding fragment thereof or the derivative.

The invention belongs to the technical field of genes, and discloses a method for efficiently expressing a foreign protein based on an NC048604-1 site in a CHO cell genome. A site for stably expressing protein in the CHO cell genome is located in the 94142000 to 94148000 basic group range of the CHO cell genome NC048604-1, and the nucleotide sequence of the site is as shown in SEQ ID NO: 1. According to the invention, different protein genes are introduced at fixed positions in a CHO cell genome, and stable expression is carried out.

The present invention provides: a drug which can improve the implantation rate of an embryo and can be used in conjunction with conventional drugs for infertility treatment; and a screening method and the like with which it is possible to reliably evaluate such a drug. Specifically, the integrin activator comprises: (1) a peptide composed of KFEERMRCKWMT, and (2) a peptide composed of KFEERMRCKWMT. (2) a peptide which is composed of KFEEERSRCKWMT; (3) a peptide comprising an amino acid sequence obtained by deleting, substituting and / or adding 1-3 amino acids in (1) or (2); or (4) a peptide obtained by binding any one of (1) to (3) to a membrane-permeable molecule. Provided are an artificial uterus and a screening method based on an implantation reproduction test system using a fertilized egg (for example, an embryo developed to an implanted blastocyst), the artificial uterus comprising: a hydrogel containing endometrial stromal cells and having an extracellular matrix as a main component; and a uterine epithelial organoid configured to be surrounded by the hydrogel.

The invention relates to the technical field of virology, immunology and biomedicine, in particular to a human metapneumovirus F protein mutant and application thereof. The human metapneumovirus F protein mutant provided by the invention has stable prefusion conformation and high expression quantity, and can form a stable trimer, so that the human metapneumovirus F protein mutant can be used for HMPV vaccine development. The F protein mutant provided by the invention has excellent immunogenicity, and can induce excellent immune response when being used together with an HA201 composite adjuvant (QS21 + MPL liposome).

A pharmaceutical composition according to an aspect can be applied to the prevention, treatment or the like of endometrial damage, Asherman's syndrome, or complications thereof by: reducing the level of collagen accumulation in the endometrium; increasing the expression level of VEGF; increasing the expression level of Ki67; increasing the expression level of Itgb3; increasing the expression level of Spp1; increasing the number of implantation sites; decreasing the expression levels of fibrosis-related factors; decreasing the expression levels of metabolism-related factors; increasing ATP production; and regulating the expression levels of mitochondrial function-related factors.

The present disclosure relates to novel antibodies binding to GPC3 or antigen-binding fragments thereof. These anti-GPC3 antibodies or fragments thereof preferably don't comprise lysine residues within their CDRs and are therefore especially suitable for conjugation. The present disclosure further relates to targeted radionuclide conjugates such as targeted actinium-225 conjugates (TACs). Preferred are TACs of formula (I) comprising the anti-GPC3 antibodies according to the present disclosure or fragments thereof. Said antibodies or antigen binding fragments thereof, and / or said antibody conjugates and / or said TACs are useful in diagnostics and / or therapy, preferably in therapy, more preferably in treating cancer, most preferably in treating hepatocellular carcinoma (HCC). Provided are pharmaceutical compositions and kits with instructions for use comprising these antibodies, functional fragments and conjugates. The disclosure further provides methods and tools to generate these antibodies, functional fragments and conjugates.

The present disclosure provides anti-TNFR2 (tumor necrosis factor receptor 2) antibodies, antigen-binding fragments thereof, and uses thereof.

The invention relates to the technical field of genetic engineering, in particular to recombinant humanized collagen and a preparation method thereof. The recombinant humanized III-type collagen provided by the invention can be efficiently and stably expressed under three expression systems of yeast, escherichia coli and CHO cells, and has biological activity superior to that of commercially available collagen products. The recombinant humanized III-type collagen disclosed by the invention has structural characteristics and functional activity similar to those of natural collagen, so that the recombinant humanized III-type collagen has wide application prospects in the aspects of biomedical materials, tissue engineering products, cosmetics, foods, health care products or medicines, medical instruments, medical cosmetology and the like.

The invention relates to an anti-human HHLA2 nano antibody and application thereof, a variable region of the nano antibody comprises CDR1, CDR2 and CDR3, an amino acid sequence of the CDR1 comprises any one of sequences as shown in SEQ ID NO: 29-36 or a mutation thereof, an amino acid sequence of the CDR2 comprises any one of sequences as shown in SEQ ID NO: 37-46 or a mutation thereof, an amino acid sequence of the CDR3 comprises any one of sequences as shown in SEQ ID NO: 47-56 or a mutation thereof, and the variable region of the nano antibody comprises CDR1, CDR2 and CDR3. The mutation is the substitution, insertion or deletion of 1, 2, 3 or 4 amino acids in the amino acid sequence. The nano antibody disclosed by the invention can be specifically combined with tumor cells expressing human HHLA2, and the killing effect of immune cells on the tumor cells can be improved by blocking a signal channel between the HHLA2 and KIR3DL3.

The invention discloses a preparation method and application of a conditioned culture solution for improving the development rate of bovine in-vitro embryos. The preparation method comprises the following steps: culturing immortalized bovine endometrial epithelial cells by using a DMEM / F12 cell culture solution containing 10% FBS, collecting the cell culture solution in the culture process, and filtering to obtain an immortalized bovine endometrial epithelial cell conditional culture solution, namely the conditional culture solution capable of improving the development rate of the bovine in-vitro embryos. The prepared conditioned culture solution can simulate a liquid environment of an in-vivo environment, is used for culturing in-vitro embryos such as parthenogenetic activated embryos and in-vitro fertilized embryos, improves the cleavage rate and blastocyst rate of the in-vitro embryos and improves the development rate of the in-vitro embryos of cattle.

The invention belongs to the technical field of gene engineering, and discloses a cat serum albumin mutant as well as a CHO cell expression method and application thereof. The invention provides a cat serum albumin mutant Mut-FSA for the first time, and an optimized Mut-FSA sequence is finally formed by replacing the 558th K at the tail end of an FSA amino acid sequence with R. Compared with non-mutated FSA, the Mut-FSA can show more remarkable curative effect advantages in treatment intervention of cat hypoproteinemia or acute hemorrhage, in addition, the Mut-FSA not only can enable cats suffering from the hypoproteinemia to achieve rapid correction of serum albumin concentration within 24 hours after treatment intervention, but also can effectively improve the serum albumin level and overall prognosis of the cats. The recombinant FSA prepared by the invention not only can provide a more effective innovative therapy for cat hypoproteinemia or acute hemorrhage, but also has wide application prospect and industrialization value.

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and / or anti-CTLA-4 antibodies), is also provided.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

The invention relates to the technical field of biology, and particularly provides an endometrial organ culture method. By optimizing the endometrial organoid differentiation culture system, compared with an existing culture mode, the optimized culture system is easy to operate, the organoid with more complete physiological functions can be prepared without co-culture with stromal cells, continuous culture can be conducted for at least one year or above, and the obtained organoid is complete in secretion function and free of secondary pollution. The phenotype of cilia cells is more obvious.